Tag: sacituzumab govitecan-hziy

Home / sacituzumab govitecan-hziy

Categories

Sacituzumab govitecan-hziy is approved by FDA for HR-positive breast cancer

Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+...
sacituzumab-govitecan-hziy

Scan the code